口服葡萄糖耐受性测试:使用不同的饮用溶液改变了结果吗?
Sabine Schipf1, Oliver Kuß2,3,4, Barbara Thorand3,5,6
1Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
概括
两种口服葡萄糖耐受性测试 (oGTT) 溶液,一种商业化的Accu-Chek Roche和一种标准化的NRF 13.8,在2小时葡萄糖水平或胃肠道副作用方面没有显著的临床差异. 这一发现支持了这些解决方案在诊断测试中的可互换性.
科学领域:
- 内分泌学 在内分泌学.
- 临床化学 临床化学
- 公共卫生研究 公共卫生研究
背景情况:
- 选择口服葡萄糖耐受性测试 (oGTT) 的饮用溶液可以影响结果和患者体验.
- 标准化协议对于准确的糖尿病诊断和管理至关重要.
研究的目的:
- 为了比较商业Accu-Chek Roche溶液与标准化NRF 13.8 oGTT溶液对2小时葡萄糖值的影响.
- 评估和比较与每个oGTT溶液相关的胃肠道副作用.
主要方法:
- 德国国家队列 (NAKO) 参与者的小组接受了Accu-Chek Roche或NRF 13.8溶液,用于75g的oGTT.
- 参与者根据研究中心,性别,年龄,BMI和禁食葡萄糖相匹配.
- 使用类内相关性和布兰德-阿尔特曼图表分析了2小时的葡萄糖值;也计算了变化系数.
主要成果:
- 两种溶液之间的2小时葡萄糖的平均差异为-3.4 mg/dL,没有系统的变化模式.
- 2小时葡萄糖的类内相关性为22%,变化系数相似 (25%).
- 恶心或吐等胃肠道症状发生在不到0.1%的参与者身上,解决方案之间没有显著差异.
结论:
- 艾库-切克·罗什和NRF 13.8 oGTT溶液产生了可比的2小时葡萄糖值和胃肠道副作用概况.
- 这些发现表明,这两种解决方案在临床上可以互换进行口服葡萄糖耐受性测试.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
Hypoglycemia and Glucagon
146
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
146
Glucose Homeostasis: Regulation of Blood Glucose
1.3K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153


